DECR2

Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] · Q9NUI1 · DECR2 on Sugi Atlas →

0 patent compounds predicted against DECR2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to DECR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone. PHASE4COMPLETED
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
Betaine and Peroxisome Biogenesis Disorders PHASE3COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Cholic Acid for Hepatic Steatosis in Lipodystrophy PHASE2COMPLETED
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris PHASE1/PHASE2UNKNOWN
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia PHASE2WITHDRAWN
Smith-Lemli-Opitz Syndrome and Cholic Acid PHASE1/PHASE2COMPLETED
Fibrates in Pediatric Cholestasis PHASE2COMPLETED
Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects PHASE2COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease EARLY_PHASE1COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study nanCOMPLETED
A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome nanWITHDRAWN
Genetic Origin of Lipid Disorders nanUNKNOWN
Familial Partial Lipodystrophy Study nanCOMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl nanCOMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes nanCOMPLETED
Dietary Fatty Acids, PPAR Activated Genes, and CHD nanCOMPLETED
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy nanNOT_YET_RECRUITING
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED
Omics-based Predictors of NAFLD/Potential NASH nanUNKNOWN
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes nanRECRUITING
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism nanNO_LONGER_AVAILABLE
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing nanCOMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Gene Polymorphisms Influencing Steroid Synthesis and Action nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a DECR2 binder may also engage these)

ProteinNameSimilarity
Q5RBV3 1.000 Q5RBV3 →
Q9Z2M4 0.996 Q9Z2M4 →
Q9WV68 0.994 Q9WV68 →
Q6NV34 0.992 Q6NV34 →
Q9LTV6 0.991 Q9LTV6 →
Q9WVK3 0.988 Q9WVK3 →
P32573 0.986 P32573 →
Q93761 0.985 Q93761 →
Q9BY49 0.984 Q9BY49 →
Q9JIF5 0.984 Q9JIF5 →
Q22230 0.983 Q22230 →
Q5RCF8 0.983 Q5RCF8 →
Q9CQ62 0.982 Q9CQ62 →
A0A3G9HAL8 0.982 A0A3G9HAL8 →
A0A1B2CTA9 0.981 A0A1B2CTA9 →
A3F5F0 0.981 A3F5F0 →
A0A162J3X8 0.981 A0A162J3X8 →
A0A144Y7G4 0.981 A0A144Y7G4 →
L0E4F8 0.980 L0E4F8 →
A0A6S6QNE4 0.980 A0A6S6QNE4 →
A0A0F7U1Z1 0.980 A0A0F7U1Z1 →
A0A8F5XX49 0.980 A0A8F5XX49 →
O93868 0.980 O93868 →
A0A0B4GU97 0.980 A0A0B4GU97 →
A0A8I6GJ95 0.980 A0A8I6GJ95 →
A0A0B4GT47 0.979 A0A0B4GT47 →
Q99MZ7 0.979 Q99MZ7 →
A0A3Q8GYY4 0.979 A0A3Q8GYY4 →
P9WES5 0.979 P9WES5 →
Q99LB2 0.979 Q99LB2 →